The master trial approach has become a popular concept in oncology, but as FDA, industry and academia prepare a master protocol for metastatic breast cancer, they are also grappling with the challenge of capturing rational combinations that can help get ahead of resistance and better treat patients.
Stakeholders, which also included patient advocates and leading practitioners, convened in late October to discuss next-generation oncology trials for metastatic breast cancer, with the goal of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?